Follow-up phase III data showed Roche ’s Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death

Roche today announced follow-up data from the phase III ALEX study, showing that, as an initial treatment, Alecensa ® (alectinib) significantly reduced the risk of disease progression or death (progression-free survival; PFS) by 57% (hazard ratio [HR]= 0.43, 95% CI: 0.32-0.58) compared to crizotinib after two years of follow-up in people with anaplastic lymphoma kinase (ALK)-positive metastatic (advanced) non-sm all cell lung cancer (NSCLC), as assessed by the investigator.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news